Skip to main content
. 2013 Dec 12;134(4):992–1000. doi: 10.1038/jid.2013.476

Figure 2.

Figure 2

Tofacitinib inhibits OT-I cell activation in skin-draining lymph nodes (SDLNs) of mice with graft-versus-host disease (GVHD)-like disease. (a) The plots represent serum levels of IFN-γ and tumor necrosis factor (TNF)-α in mice treated with vehicle (white) or tofacitinib daily at 12.5 (grey) or 50 mg kg–1 BID (black) 5 days after cell transfer. The bars show means. *P<0.05, U-test. (b–d) FACS analysis of pooled SDLN cells taken 4 days after the transfer of green fluorescence protein transgenic+ (GFP+) OT-I cells into keratin 14 promoter-membrane OVA transgenic (K14-mOVA) mice (five mice in each group) show the proportions of recovered GFP+OT-I cells in SDLNs from vehicle-treated (left panel) or tofacitinib-treated (50 mg kg–1 ;right panel) mice (b). Expression of Vα2, Vβ5, CD25, and CD62L (c), and the production of IFN-γ and TNF-α (d) of GFP+OT-I cells in SDLNs from vehicle-treated mice or mice treated with tofacitinib 50 mg kg–1 BID. Data are representative of four separate experiments. OT-I cells, transgenic T cells.